Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Immunoglobulin A Nephropathy (IgAN) is the most common form of primary glomerulonephritis (GN) globally, predominantly affecting males between 30–40 years of age, often following infections such as tonsillitis, pharyngitis, pneumonia, and urinary tract infections (UTIs). Clinically, it presents with a wide spectrum including proteinuria, hematuria, hypertension, nephrotic and nephritic syndromes, acute kidney injury, and chronic renal failure. Diagnosis is confirmed by renal biopsy with positive immunofluorescence (IF) for mesangial IgA deposits. Although IgAN is also frequently encountered in India, limited studies exist due to the previously low availability of IF facilities.
Management focuses on slowing disease progression using antiproteinuric measures, primarily angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), especially in patients with persistent proteinuria >1 g/day. In patients with active histological lesions or declining renal function, immunosuppressive therapy—including corticosteroids and adjunct agents—is considered based on risk stratification. Histologically, the Oxford Classification (MEST-C score)—comprising Mesangial hypercellularity (M), Endocapillary hypercellularity (E), Segmental glomerulosclerosis (S), Tubular atrophy/interstitial fibrosis (T), and Cellular/fibrocellular crescents (C)—is widely used for prognostic evaluation.
The aim of this study was to analyze the clinicopathological features of IgAN and assess the clinical correlation with histopathological findings, including MEST-C scoring, and evaluate patient response to antiproteinuric and immunosuppressive therapies in a cohort from Central India.
The study was based on a retrospective analysis of renal biopsy data and clinical manifestations of the disease. Consecutive 271 biopsy-proven IgAN cases of male (66.42%) and female (33.58%) patients were investigated. Renal biopsies were reviewed using the new Oxford classification assessing the MEST (mesangial hypercellularity, endocapillary hypercellularity, segmental sclerosis/adhesion, tubular atrophy/interstitial fibrosis) score. The mean rate of renal function decline was expressed as a slope of eGFR during the follow-up (FU) dividing delta GFR with the Follow Up years.
The mean age of the patients was 37.16±11.99 years with median of 36. M1 (>50% Glomeruli), E1, T2 (>50% Tubules) and C2 (>25% Glomeruli) was present in 25.5%, 19.6%, 44.6%, 7% and 3.7% of the subjects respectively. Higher segmental sclerosis/adhesion and tubular atrophy/interstitial fibrosis were significantly associated with presence of TMA. Creatinine and eGFR was significantly associated with M1 (>50% Glomeruli), E1, T2 (>50% Tubules) and C2 (>25% Glomeruli).
IgA Nephropathy in India predominantly affects young individuals. A significant correlation was observed between the presence of renal failure and higher M, E, S, and T scores of the Oxford MEST-C classification, highlighting the prognostic value of histopathological grading. These findings emphasize the importance of early detection, routine use of immunofluorescence, and the need for tailored therapeutic strategies based on clinicopathological correlation.
